1. 2637 Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1™ trial of first-line gemcitabine/cisplatin plus apatorsen or placebo. (September 2015) Authors: Petrylak, D.; Eigl, B.; Senkus, E.; Loriot, Y.; Twardowski, P.; Castellano, D.; Blais, N.; Sridhar, S.; Sternberg, C.; Retz, M.; Blumenstein, B.; Jacobs, C.; Stewart, P.; Bellmunt, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S525 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 4BA A phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castrate resistant prostate cancer (mCRPC). (September 2015) Authors: Carducci, M.; Armstrong, A.; Pili, R.; Ng, S.; Huddart, R.; Agarwal, N.; Khvorostenko, D.; Lyulko, O.; Brize, A.; Vogelzang, N.J.; Delva, R.; Harza, M.; Thanos, A.; James, N.; Werbrouck, P.; Bögemann, M.; Hutson, T.; Milecki, P.; Nederman, T.; Sternberg, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S713 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study. (February 2017) Authors: Necchi, A.; Bellmunt, J.; De Wit, R.; Vaughn, D.; Fradet, Y.; Lee, J.L.; Fong, L.; Vogelzang, N.; Climent, M.; Petrylak, D.; Choueiri, T.; Gerritsen, W.; Gurney, H.; Quinn, D.; Culine, S.; Sternberg, C.; Mai, Y.; Puhlmann, M.; Perini, R.; Bajorin, D. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗